In This Section      
Print This Page

Search Results

E1Z11 A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Protocol Number:
Phase IV
Vered Stearns
Suburban Hospital
Sibley Memorial Hospital
Johns Hopkins Kimmel Cancer Center in Baltimore
This research is being done to find out what effects, good and/or bad, that anastrozole has on you and whether your genes can help explain how anastrozole affects you. Specifically, many women who take anastrozole, or one of the other aromatase inhibitors (letrozole or exemestane) during treatment for breast cancer report muscle and joint aches; however, the reasons that lead to these symptoms are not known. These symptoms have been designated �aromatase inhibitor-associated musculoskeletal syndrome� (or AIMSS). Small studies have suggested that a person�s genetic information may help us to develop a way to predict who would develop side effects and how best to treat them, and we hope to collect information in this study to look at this more closely. In addition, we hope to look at how the side effects from hormone therapy influence quality of life and a patient�s willingness to continue hormonal treatment.
Generally healthy, postmenopausal women who are prescribed the aromatase inhibitor anastrozole as treatment for their breast cancer may join. They may not have received anastrozole or any other aromostase inhibitor in the past for the treatment of their cancer. They may have received other treatment for their cancer.
If you agree to participate in this study, under the direction of your doctor, you will begin taking anastrozole (1 mg tablet) by mouth each day. You will also complete questionnaires throughout the study. You will be followed for 12 months as part of the study.
Last Update
01/21/2018 05:03 AM